US FDA gets tough on financial disclosures by clinical investigators
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration has substantially revised its guidance on the disclosure of financial interests by clinical investigators and is seeking stakeholder feedback on the draft document1,2. The revised guidance addresses concerns that the FDA does not do enough to guard against financial conflicts of interest among physicians, who carry out clinical trials of pharmaceuticals and medical devices that have yet to receive marketing authorisation.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.